(HealthDay)—The safety profile of oral propranolol seems to be good for children with infantile hemangioma, according to a study published online May 29 in Pediatrics.
Catherine Droitcourt, M.D., from the University of Rennes in France, and colleagues used the French National Health Insurance system to perform a survey of a nationwide cohort of children aged
The researchers found that two cardiovascular events, 51 respiratory events, and three metabolic events were observed in the healthy population (SMR, 2.8 [0 to 6.7], 1.7 [1.2 to 2.1], and 5.1 [0 to 10.9], respectively). In patients with an underlying disease, usually congenital heart disease, there were 11 cardiovascular events (SMR, 6 [2.5 to 9.6]). Among children with underlying disease, SMRs were not significantly elevated for respiratory or metabolic events.
“In this study on a large continuous nationwide claims database, we confirm the safety profile of oral propranolol in healthy children to be good,” the authors write.
Propranolol effective for infantile hemangioma
Abstract/Full Text (subscription or payment may be required)